ENvue Medical Appoints Marc Waldman as VP of Commercial to Drive Revenue Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
Source: Globenewswire
- Leadership Change: ENvue Medical has appointed Marc Waldman as Vice President of Commercial, where he will lead the company's U.S. commercialization strategy across 38 hospitals, aiming to accelerate revenue growth and expand market presence.
- Extensive Industry Experience: Waldman brings over 35 years of experience in the medical device industry, having previously worked at NeoMed and Avanos Medical, where he successfully increased North American sales from approximately $39 million to $70 million, showcasing his exceptional sales leadership.
- Strategic Execution: During his tenure at Avanos, Waldman guided the organization through a significant transition from a dealer-only model to a hybrid structure, leveraging both direct and dealer partnerships to enhance market competitiveness and optimize the business model.
- Industry Influence: As Chairperson of the Global Enteral Device Supplier Association, Waldman plays a crucial role in advancing enteral safety standards, further enhancing ENvue's influence and reputation within the healthcare industry.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on FEED
About FEED
ENvue Medical, Inc. is a medical technology company advancing both non-invasive and minimally invasive solutions across clinical and home care settings. Its segments include NanoVibronix, ENvue and Corporate. NanoVibronix is engaged in selling its products directly to patients as well as through distributor agreements. ENvue is engaged in selling its systems and Nasoenteral tubes and related services. The Company focuses on two distinct technology platforms: Acoustic-based therapeutic technologies, including PainShield and UroShield, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms. The ENvue Navigation Platform, which is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Meta Platforms Reports Strong Q4 Earnings, Shares Surge
- Strong Financial Results: Meta reported fourth-quarter revenue of $59.89 billion, exceeding analyst expectations of $58.30 billion, indicating robust performance in the recovering advertising market, which is likely to drive further stock price increases.
- Earnings Growth: The company posted adjusted earnings of $8.88 per share, surpassing the forecast of $8.16 per share, reflecting significant improvements in cost control and operational efficiency, thereby boosting investor confidence.
- Stock Price Surge: Following the earnings report, Meta's shares jumped 8.2% in pre-market trading to $723.70, indicating a positive market sentiment towards the company's growth prospects, which may attract more investor interest.
- Optimistic Sales Guidance: Meta's first-quarter sales guidance exceeded market expectations, further solidifying its leadership position in the digital advertising space and suggesting continued benefits from the recovery in advertising spending.
Continue Reading
ENvue Partners with U-Deliver for Nationwide Syringe Distribution
- Stock Surge: ENvue Medical, Inc. (FEED) shares soared 138% on Wednesday following the announcement of a distribution agreement with U-Deliver, indicating strong market enthusiasm for its new product line.
- Product Launch: The recently launched ENFit syringe line is designed to meet clinical needs for both feeding and medication delivery without requiring a prescription, enhancing its competitive edge in the market.
- Distribution Channel Expansion: The new agreement will leverage U-Deliver's digital and wholesale channels to broaden access to the ENFit syringes, which is expected to significantly increase market penetration.
- Market Sentiment Shift: On Stocktwits, retail sentiment around FEED shifted from 'bearish' to 'extremely bullish', with message volume rising from 'low' to 'extremely high', reflecting investor optimism about the company's future prospects.
Continue Reading